A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade

Immune checkpoint blockade (ICB), therapies that target the PD-1 pathway, CTLA-4 pathway, and other checkpoint pathways, lead to durable responses in many cancer types. Since only a minority of patients respond to ICB, it may be useful to identify the future responders early in the course of treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Panda, Anshuman, Betigeri, Anil, Ganesan, Shridar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928072/
https://www.ncbi.nlm.nih.gov/pubmed/35309122
http://dx.doi.org/10.3389/fgene.2022.706468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928072/
https://www.ncbi.nlm.nih.gov/pubmed/35309122
http://dx.doi.org/10.3389/fgene.2022.706468

Ejemplares similares